|
1）Bousquet J, Lockey R, Malling HJ. World health organization position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1988; 53(suppl): 20-7
|
|
|
|
|
2）Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nature Rev Immunol. 2006; 6: 148-58
|
|
|
|
|
|
3）Faria AMC, Weiner HL. Oral tolerance. Immunol Rev. 2005; 206: 232-59
|
|
|
|
|
4）Mayer L, Shao L. Therapeutic potential of oral tolerance. Nature Rev Immunol. 2004; 4: 407-19
|
|
|
|
|
|
5）Akbari O, Dekruyff RH, Umetsu DT. Pulmonary dendric cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2001; 2: 725-31
|
|
|
|
|
|
6）Wakkach A, Fournier N, Brun V, et al. Characterization of dendric cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003; 18: 605-17
|
|
|
|
|
|
7）Hirahara K, Hisatsune T, Nishijima K, et al. CD4＋T cells anergized by high dose feeding establish oral tolerance to antibody responses when transferred in Scid and nude mice. J Immunol. 1995; 154: 6238-45
|
|
|
|
|
|
8）Chen Y, Inobe J, Marks G, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 1995; 376: 177-80
|
|
|
|
|
|
9）Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001; 182: 207-14
|
|
|
|
|
|
10）Levings MK, Sangregorio R, Galbiati F, et al. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol. 2001; 166: 5530-9
|
|
|
|
|
|
11）Zhang X, Izkson L, Liu L, et al. Activation of CD25＋CD4＋ regulatory T cells by oral antigen administration. J Immunol. 2001; 167: 4245-53
|
|
|
|
|
|
12）Mellow AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nature Rev Immunol. 2004; 4: 762-74
|
|
|
|
|
|
13）Akidis M, Blaser K, Akdis CA. T regulatory cells in allergy: Novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol. 2005; 116: 961-8
|
|
|
|
|
|
14）Akidis M, Akidis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007; 119: 780-9
|
|
|
|
|
|
15）Mascarell L, Van overtvelt L, Moingeon P. Novel ways for immune intervention in immunotherapy: Mucosal allergy vaccines. Immunol Allergy Clin N Am. 2006; 26: 283-306
|
|
|
|
|
|
16）Punnonen J. Molecular breeding of allergy vaccines and antiallergic cytokines. Int Arch Allergy Immunol. 2000; 121: 173-82
|
|
|
|
|
|
17）Niederberger V, Valenta R. Molecular approaches for new vaccines against allergy. Expert Rev Vaccines. 2006; 5: 103-10
|
|
|
|
|
|
18）Hoyne G, kristensen NM, Yssel H, et al. Peptide modulation of allergen-specific immune responses. Curr Opin Immunol. 1995; 7: 757-61
|
|
|
|
|
|
19）Larche M, Wriath DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nature Med. 2005; 11: 569-76
|
|
|
|
|
|
20）Linhart B, Valenta R. Molecular design of allergy vaccines. Curr Opin Immunol. 2005; 17: 646-55
|
|
|
|
|
|
21）Hirahara K, Saito S, Serizawa N, et al. Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific Th1 and Th2 cell responses in Cry j 2-primed mice. J Allergy Clin Immunol. 1998; 102: 961-7
|
|
|
|
|
|
22）Qu LQ, Takaiwa F. Evaluation of tissue specificity and expression strength of rice seed component gene promoters in transgenic rice. Plant Biotechnol J. 2004; 2: 113-25
|
|
|
|
|
|
23）Takaiwa F, Takagi H, Hirose S, et al. Endosperm tissue is good production platform for artificial recombinant proteins in transgenic rice. Plant Biotech J. 2007; 5: 84-92
|
|
|
|
|
|
24）Takaiwa F. Tranasgenic rice seed as a nutriceutical delivery system. CAB Rev. 2007; 2: http://www.cababstractsplus.org/cabreview
|
|
|
|
|
|
25）Takagi H, Saito S, Yang L, et al. Oral immunotherapy against a pollen allergy using a seed-based peptide vaccine. Plant Biotech J. 2005; 3: 521-33
|
|
|
|
|
|
26）Kawagoe Y, Suzuki K, Yasuda H, et al. The critical role of disulphide bond formation in protein sorting in the endosperm of rice. Plant Cell. 2005; 17: 1141-53
|
|
|
|
|
|
27）Nochi T, Takagi H, Yuki Y, et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci USA. 2007; 104: 10986-91
|
|
|
|
|
|
28）Shrawat AK, Lorz H. Agrobacterium-mediated transformation of cereals: a promising approach crossing barriers. Plant Biotech J. 2006; 4: 575-603
|
|
|
|
|
|
29）Endo S, Sugita K, Sakai M, et al. Single-step transformation for generating marker-free transgenic rice using the ipt-type MAT vector system. Plant J. 2002; 30: 115-22
|
|
|
|
|
|
30）Takagi H, Hiroi H, Yang L, et al. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci USA. 2005; 102: 17525-30
|
|
|
|
|
|
31）Takaiwa F. A rice-based edible vaccine expressing multiple T-cell epitopes to induce oral tolerance and inhibit allergy. Immnol Allergy Clin N Am. 2007; 27: 129-39
|
|
|
|
|
|
32）Hirahara K, Tatsuta T, Takatori T, et al. Preclinical evaluation of an immunotherapeutic peptide comprising T-cell determinants of Cry j1 and Cry j2, the major Japanese cedar pollen allergens. J Allergy Clin Immunol. 2001; 108: 94-100
|
|
|
|
|
|
33）Takagi H, Hirose S, Yasuda H, et al. Biochemical safety evaluation of transgenic rice seeds expressing T cell epitopes of Japanese cedar pollen allergens. J Agricul Food Chem. 2006; 54: 9901-5
|
|
|
|
|